Rep. Byron Donalds Purchases Shares of Zoetis Inc. (NYSE:ZTS)

Posted by Bonnie Powley on Jul 19th, 2026

Representative Byron Donalds (Republican-Florida) recently bought shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on July 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in Zoetis stock on June 9th. The trade occurred in the Representative’s “MORAN WEALTH IRA” account.

Representative Byron Donalds also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Cadence Design Systems (NASDAQ:CDNS) on 6/5/2026.
Sold $1,001 – $15,000 in shares of Monolithic Power Systems (NASDAQ:MPWR) on 6/5/2026.

Zoetis Stock Down 0.6%

Shares of Zoetis stock traded down $0.47 on Friday, reaching $76.44. The company’s stock had a trading volume of 7,544,382 shares, compared to its average volume of 5,801,801. Zoetis Inc. has a 52 week low of $71.47 and a 52 week high of $160.48. The firm’s fifty day simple moving average is $77.33 and its two-hundred day simple moving average is $106.03. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The company has a market capitalization of $32.05 billion, a price-to-earnings ratio of 12.68, a P/E/G ratio of 1.20 and a beta of 0.75.

Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.87 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

Positive Sentiment: Zoetis was named as title sponsor of PawsitiveIntelligence.ai, adding a small brand-visibility and industry-partnership angle. Pawsitive Holdings Announces Zoetis as Title Sponsor of PawsitiveIntelligence.ai
Positive Sentiment: Some commentary argued Zoetis offers an attractive risk-reward setup, suggesting a more constructive long-term view despite recent volatility. Zoetis: An Attractive Risk-Reward Opportunity
Neutral Sentiment: Zoetis’ upcoming second-quarter earnings report is getting attention, with analysts expecting modest growth and investors watching for updated guidance and commentary on diagnostics demand. Zoetis Earnings Preview: What to Expect
Neutral Sentiment: Zoetis announced it will acquire VitalRADS, a veterinary teleradiology platform, which could support its diagnostics strategy and AI-enabled offerings. Zoetis Gains as VitalRADS Deal Boosts Diagnostics Narrative
Negative Sentiment: Multiple law firms issued reminders and investor alerts tied to a securities class action against Zoetis, reinforcing concerns about litigation risk and possible reputational damage. Deadline Alert for CALX, AVAV, ZTS, LCID
Negative Sentiment: Additional class-action notices specifically target Zoetis shareholders, underscoring that the lawsuit remains an active overhang for the stock. ZTS Shareholder Alert
Negative Sentiment: The legal backdrop follows earlier reports alleging investor harm and reminding shareholders of the same July 27 deadline, keeping sentiment cautious. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Hedge Funds Weigh In On Zoetis

Hedge funds have recently made changes to their positions in the business. Global Wealth Strategies & Associates purchased a new position in Zoetis in the 4th quarter worth approximately $25,000. Prosperity Bancshares Inc bought a new position in Zoetis in the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC purchased a new stake in Zoetis during the 1st quarter valued at approximately $28,000. Lodestone Wealth Management LLC bought a new stake in shares of Zoetis during the fourth quarter valued at approximately $30,000. Finally, Root Financial Partners LLC raised its position in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after buying an additional 103 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. TD Cowen cut their target price on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research report on Tuesday, June 30th. Barclays dropped their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Citigroup cut their price target on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday, May 18th. Stifel Nicolaus reduced their price target on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research report on Friday, June 26th. Finally, Argus reaffirmed a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Hold” and a consensus price target of $120.83.

Check Out Our Latest Analysis on ZTS

Insider Buying and Selling

In related news, Director Paul Bisaro purchased 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the purchase, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael B. Mccallister acquired 3,000 shares of the company’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders purchased 11,650 shares of company stock worth $886,384. 0.22% of the stock is owned by insiders.

About Representative Donalds

Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida’s 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.

Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida’s 19th Congressional District. He declared candidacy for the 2026 election.

Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor’s degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.

Zoetis Company Profile

(Get Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.